Review

Exogenous Contrast Agents in Photoacoustic Imaging: An In Vivo Review for Tumor Imaging

Afifa Farooq 1, Shafiya Sabah 1, Salam Dhou 1,2,*, Nour Alsawaftah 1 and Ghaleb Husseini 1,3,*

1 Biomedical Engineering Graduate Program, American University of Sharjah, Sharjah 26666, United Arab Emirates; g00051241@alumni.aus.edu (A.F.); g00079837@alumni.aus.edu (S.S.); nalsawaftah@aus.edu (N.A.)
2 Department of Computer Science and Engineering, American University of Sharjah, Sharjah 26666, United Arab Emirates
3 Department of Chemical Engineering, American University of Sharjah, Sharjah 26666, United Arab Emirates
* Correspondence: sdhou@aus.edu (S.D.); ghusseini@aus.edu (G.H.); Tel.: +971-6-515-2943 (S.D.);
+971-6-515-2970 (G.H.)

Abstract: The field of cancer theranostics has grown rapidly in the past decade and innovative ‘biosmart’ theranostic materials are being synthesized and studied to combat the fast growth of cancer metastases. While current state-of-the-art oncology imaging techniques have decreased mortality rates, patients still face a diminished quality of life due to treatment. Therefore, improved diagnostics are needed to define in vivo tumor growths on a molecular level to achieve image-guided therapies and tailored dosage needs. This review summarizes in vivo studies that utilize contrast agents within the field of photoacoustic imaging—a relatively new imaging modality—for tumor detection, with a special focus on imaging and transducer parameters. This paper also details the different types of contrast agents used in this novel diagnostic field, i.e., organic-based, metal/inorganic-based, and dye-based contrast agents. We conclude this review by discussing the challenges and future direction of photoacoustic imaging.

Keywords: photoacoustic imaging; exogenous contrast agents; tumor imaging

1. Introduction

Photoacoustic imaging (PAI) [1] is a breakthrough invention in the field of bioengineering [2]. It involves the transmission of a short pulse of laser non-invasively onto the tissues. The absorbed light changes into heat, causing the thermal excitation and expansion of the tissues. This results in generating acoustic waves that can be detected via a transducer [3]. PAI offers several advantages, including the utilization of non-ionizing radiation, the ability to reach greater depths, as well as increased resolution and optical contrast [4]. The discovery of the photoacoustic (PA) effect dates back to 1880, when the phenomenon was first observed by Alexander Graham Bell [5]. Bell reported that sound is produced upon the illumination of solid materials with a light beam. The light beam must be of a vibratory nature for the PA effect to be observed. As laser technology became available in the 1960s, the PA effect began to be considered for practical applications. By the 1990s, researchers working in the field recognized the potential use of the PA effect for medical imaging [6–9]. R. Esenaliev et al. [6] studied the feasibility of using optoacoustic laser imaging for the early detection of breast cancer. In the phantom study performed in [6], it was observed that in comparison to ultrasound (US) and mammography, the new laser optoacoustic imaging technique offers images with improved contrast for phantoms that were dense and uniform acoustically. Over time, with improvements in hybrid imaging technologies and advancements in image reconstruction algorithms, it became possible to use the PA effect for in vivo studies [10–12]. In the past few years, a significant evolution in
PAI is evident, which will be further discussed in this paper with a focus on contrast agents used in in vivo PAI studies (refer to Figure 1).

Materials that absorb the transmitted optical signal can be endogenous, i.e., present naturally in the body, or exogenous, i.e., synthesized/developed outside the body. In vivo studies have been performed to detect tumors using probes that can be activated by enzymes related to cancer [13], probes based on peptides [14], gold nanoparticles [15,16], dyes [17–19], melanin, oxy- and deoxy-hemoglobin [20,21]. Previous reviews have summarized methods that utilize different contrast agents. However, these publications fall short of presenting the different agents based on image quality, blood circulation time, cytotoxicity levels, and laser pulse parameters. Table 1 summarizes contrast agents used for various imaging modalities.

As PAI is a low-cost, non-invasive imaging modality that uses non-ionizing laser power for the excitation of target tissues; it can provide real-time physiological information such as blood oxygenation and other structural information of the site being studied [22]. The penetration depth offered by PAI is higher than that conventionally offered by optical imaging. Apart from providing great benefits, PAI has certain limitations. Optical fluence, i.e., the deposited optical energy on the target region through laser, is depth-dependent and can lead to lower amplitudes of the PA signal arising from deep tissues and vessels [23,24]. Therefore, achieving a clinically desired penetration depth with PAI is challenging, thus limiting its use in widespread medical applications. Another challenge with PAI occurs while imaging regions with overlapping tissue types as the acoustic properties between different tissue types are not consistent [25]. In addition, the safety and compatibility of exogenous contrast agents used in PAI with the biological system need to be ensured.

Due to the rising trend of imaging tumor tissues using PAI [26–34] (see Figure 2), this review summarizes the recent major developments in PAI. It summarizes the in vivo studies that utilize different contrast agents to produce an enhanced image. Furthermore, this review aims to classify these contrast agents into organic-based, metal-based, and dye-based agents with a detailed commentary on significant points of interest. The rest of the paper is organized as follows. Section 2 discussed the contrast agents used for in vivo studies. Section 3 concludes the paper and presents the challenges facing PAI along with future research directions.
Combinations of these contrast agents can be used to create hybrid contrast agents and optimize imaging [38,39].

Table 1. Contrast agents used for different imaging modalities.

| Modality      | Commonly Used Contrast Agents                                                                 | References |
|---------------|-----------------------------------------------------------------------------------------------|------------|
| MRI           | Gadolinium, Super paramagnetic iron oxide nanoparticles (SPIONs), Carbon-13, Nanodiamonds, Carbon nanotubes, Graphene, Manganese, Silicon, Peptides | [35]       |
| CT            | Gold nanoparticles, Iodine (131I), Bismuth, Lanthanide-based (gadolinium, dysprosium, ytterbium) | [35,36]    |
| Ultrasound    | Nanobubbles, microbubbles (with modifications)                                                  | [35,37]    |
| PET           | Gold nanoparticles, Copper (64Cu), Iodine (124I), Fluorine (18F)                                | [35,38]    |
| SPECT         | Gold nanoparticles, Technetium (99mTc)                                                         | [35]       |
| Optical Imaging | Fluorescence, Quantum dots, Gold nanoparticles, Persistent luminescence nanoparticles              |            |
|               | Combinations of these contrast agents can be used to create hybrid contrast agents and optimize imaging | [38,39] |

2. Contrast Agents for In Vivo Testing

2.1. Basis of PAI and Design Considerations for Contrast Agents

PAI is based on PA tomography (PAT) that incorporates optical imaging and US. A short pulse of laser is transmitted onto/into the tissues non-invasively. The absorbed light changes into heat, causing the thermal excitation and expansion of tissues [40]. This results in generating acoustic waves that can be detected via a transducer. One of the principal subdivisions in PAT is photoacoustic microscopy (PAM). In PAM, every excitation by a laser pulse creates an image in one dimension of a point in the object. Numerous one-dimension images can be combined to form a three-dimension image without using reconstruction algorithms [3].

Endogenous and exogenous contrast agents are used in PAI. Endogenous molecules found in the body, such as melanin and hemoglobin, have broad optical absorption in the visible light and near-infrared (NIR) ranges compared to adjacent tissues, leading to strong PA contrast signals. However, information obtained by imaging a tumor in its initial phase using endogenous contrast agents is not adequate; hence, biocompatible exogenous contrast agents are used. The latter provides an enhanced signal contrast and better image quality compared to endogenous contrast agents [41].
Contrast agents in PAI are usually chosen to optimize absorption and depth in vivo. For this reason, contrast agent wavelengths should be in the NIR range. There is minimal light absorption in this region by hemoglobin above 650 nm, and by water below 900 nm [42]. More recently, the NIR-II window, in the 1000–1700 nm range, is a focus of contrast agent development as it has a greater tissue penetration depth due to lower light-tissue interaction and safe use of higher power density for light irradiation [43]. Longer penetration depth and higher contrast provided by NIR-II window compared to NIR-I window are because of reduced tissue scattering and minimal tissue absorption [44]. In short, minimal absorption means more significant penetration depths. Some of the major factors that must be taken into consideration to optimize imaging in vivo are: (1) Having long blood circulation times, i.e., these agents or nanoparticles should be able to evade the immune response by the reticuloendothelial system (RES) cells, travel across membrane barriers, and avoid elimination by renal and splenic filtration and reach the imaged tissue, (2) Being biocompatible, i.e., not cytotoxic within the concentration dosage to be administered for imaging, (3) Exhibiting a strong imaging signal to improve poor contrast, (4) Possessing biological specificity, i.e., being designed such that it can reach the imaged area in a reasonable time frame [42].

Since this review will mainly focus on imaging cancer malignancies, it is necessary to mention the three methods of tumor targeting in oncology: passive, active, and triggered targeting. Passive targeting involves the utilization of the enhanced permeability and retention (EPR) phenomenon, which increases the accumulation of nanoparticles (in the size range of 15–150 nm) at the tumor site [45]. This accumulation occurs due to the presence of underdeveloped blood vessels at tumor sites, with fenestrations and haphazard blood flow. Furthermore, due to the fast-growing nature of cancerous tissue, there are few to no lymphatic vessels, and thus, low drainage allows a 10–50 times higher accumulation than healthy tissues [46]. As mentioned earlier, several factors should be taken into consideration when designing these nanocarriers. The optimal size, 10–150 nm, is an essential factor to avoid filtration by the kidneys, and/or uptake by the liver- unless the region of interest includes these organs [45]. Active- or ligand- targeting uses receptor-mediated endocytosis to internalize nanocarriers. The surface of these drug encapsulating vehicles is decorated with targeting moieties (e.g., folic acid, estrone, Herceptin, etc.) that direct the probe to receptors overexpressed on the surface of the cancer cells. Triggered targeting can be achieved using internal and external means. Internal triggers include temperature, enzyme concentration, and pH levels, while external stimuli include US, NIR, and electromagnetic waves. As the performance of PAI is dependent on optically absorbing components within synthesized nanostructures, a combination of these components generally leads to better results. Therefore, this paper aims to broadly classify these multimodal/hybrid nanoagents based on component materials with PA functionality (while other components in the nanoagents perform either therapeutic, other imaging types or biocompatibility functions).

2.2. Organic Contrast Agents

Since each class of materials has specific advantages for different applications, the key advantage of organic contrast agents is that they are non-toxic and can degrade in living bodies. Nanosystems are the focus of current diagnostic, theranostic and drug delivery research due to the versatility of these materials. They are increasingly combined with organics nanoparticles and biodegradable polymers to build a new generation of contrast agents that enhance specific parameters. In addition, their size, shape, mechanical flexibility and surface chemistry can be modified to optimize their efficacy in clinical applications [47–49]. Due to their in vivo high biocompatibility, fluorescent nature, and modification flexibility, Xiao et al. [50] synthesized and characterized melanin carbonaceous dots (MCDs) for dual PAI and fluorescence imaging of breast cancer tumors in mice. With MCDs having an absorbance peak at 633 nm, near the infrared lower wavelength limit of 700 nm, higher spatial resolution imaging was produced for higher penetration depths. MCDs, for PAI, were combined with fluorescent imaging to improve the low
However, due to the tedious, costly, and complex synthesis of carbon dots (CDs), research groups have been extracting/deriving these CDs from natural resources such as Hypocrella bambusae (a parasitic fungus) [51], ethylene diamine, phosphoric acid and citric acid [52], and polythiophene phenylpropionic acid (refer to Figure 3) [53]. The enzyme horseradish peroxidase, derived from horseradish roots, was also used in conjunction with 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) and encapsulated in liposomes to act as an H$_2$O$_2$-responsive in vivo nanoprobe [54]. The idea behind these nanoprobes is that they will react directly with the targeted molecule and thus, exhibit high specificity to the desired molecule.

Figure 3. Chemical structures of natural sources for CDs’ production.

The nanoprobes mentioned above were used in cancer theranostics to detect H$_2$O$_2$ levels via the following method: synthesized glucose oxidase PEGylated (polyethylene glycol, PEG) liposomes, for starvation therapy in a 4T1-tumor microenvironment, were metabolized by the cancer cells to form gluconic acid and H$_2$O$_2$. The synthesized nanoprobe then detected the H$_2$O$_2$, thus, implementing an innovative theranostic strategy [55].

Since a major branch of theranostics in cancer nanomedicine deals with lipids for drug encapsulation, contrast agent encapsulation, ligand targeting, and biocompatibility coating, it is necessary to discuss polymeric nanoparticles and their role as contrast agents in PAI. Here it becomes essential to remind the reader that lipids exhibit optical absorbance but to a lesser extent compared to other endogenous contrast agents. Consequently, Liu et al. [56] synthesized two novel triblock copolymer nanosystems, poly(2-methyl-2-oxazoline)-block-poly(dimethylsiloxane)-block-poly(2-methyl-2-oxazoline) (PMOXA-b-PDMS-b-PMOXA); one with positively-charged terminal amino acid groups (P-NPs) and the other with negatively-charged terminal carboxylic groups (N-NPs). These micelles, spherical self-assembling single-layered nanocarriers with a hydrophobic core, were used to encapsulate a hydrophobic NIR photonic agent called hydrophobized phthalocyanine Zinc complex (H-PcZn) and the absorbance peak of both nanosystems was measured to be 680 nm—note that this is within the NIR window. A linear increase in the intensity of the PA signal was also observed with a logarithmic increase in the concentration of both P-NPs and N-NPs. The PA signal plateaued within 10 min of in vivo administration in mice, with an increased accumulation observed in the spleen compared to the liver and kidneys for N-NPs, whereas P-NPs exhibited increased accumulation in both the liver and spleen as compared to the kidneys and a comparatively stronger signal (by a factor of 1.5 in the spleen) in other tissues. Therefore, this signifies that organ-specific applications for each nanosystem can be developed. Still, longer incubation times are required to measure blood circulation times and the use of targeting moieties for specific tissues and tumors to enhance tumor targeting abilities [56,57] (see Table 2). In general, the advantage of using conjugated polymers, aside from their NIR absorbance/emission for PAI and photothermal therapy, is the ability to modify side chains to achieve desired characteristics such as self-assembly, increased protein corona formation for better nanoparticle biodistribution and targeted applications.
with the band gap in their $\pi-\pi^*$ electronic transition influencing emitted spectra and leading to tunable optical properties [58,59].

Table 2. Detailed Parameters for Contrast Agent Studies.

| Material                        | MCDs [58] | P-NP and N-NPs [56] | PGNR-PT6 and PGNR-PT7 [14] | MAGE-Au-PFH-NP [15] |
|---------------------------------|-----------|---------------------|-----------------------------|---------------------|
| Purpose                         | In vivo breast cancer imaging in mice | In vivo organ imaging in mice | In vivo osteosarcoma cancer imaging in mice | In vivo melanoma-tumor imaging in mice |
| No. of array elements           | 128 with a circular arc of 270° from 680 to 900 nm | 256 with a circular arc of 270° | - | - |
| Pulse duration (ns)             | 10        | 10                  | -                           | -                   |
| Repetition rate (Hz)            | 10        | 10                  | -                           | -                   |
| Central frequency (MHz)         | 5         | 5                   | 21                          | 21                  |
| Average size (nm)               | 40        | 20 for P-NP, and 100 for N-NP | 81.7 for PGNR-PT6, and 82.7 for PGNR-PT7 | 354.27              |
| Contrast                        | High      | High                | PGNR-PT6 and PGNR-PT7 enhanced contrast by 170% and 230%, respectively | High |
| Bio distribution (hours)        | 24        | 1 (more work needed)| 24                          | 24                  |
| Peak time (@Concentrationmax)   | 2         | 0.2                 | 4                           | 2                   |
| Biosafety                       | Low       | Not measured        | High                        | High               |
| Physical efficacy               | High      | High                | Very High                    | High               |

A problem associated with using US transducers is signal intensity loss due to US transducers having limited frequency range detection; therefore, a study by Kim et al. [60] used porphyrin phospholipid microbubble to produce resonance-based frequency-selective PA signals. Porphyrin, and other small-molecule organic dyes such as cyanine and squaraine, are being used increasingly due to their flexibility for structural modification and faster clearance with porphyrin being used as contrast and phase-change from nanodroplets to microbubbles for both ultrasound and PAI [61,62]. Theranostic molecular engineered dyes such as heptacyclic B, O-chelated BODIPY organic molecules have also demonstrated 14 times enhancement in PAI contrast post 10 h injection along with 58.7% photothermal conversion for hyperthermic tumor ablation [63]. Development of self-assembling pH-sensitive charge-transfer nanocomplexes by 3,3′,5,5′-tetramethylbenzidine within the NIR-II window has shown good contrast up to 5 cm and can be further investigated for NIR-II PA contrast agents [64]. Similarly, Pu et al. [65] used the electronic and optical properties of semiconducting oligomers and BODIPY dyes. The former acted as a PA matrix and the latter acted as PA signal enhancer and pH indicator for improved ratiometric response and increased pH sensitivity. Another study used oligomerization to its advantage for PA signal modulation based on intramolecular interactions [66]. Recent reviews summarizing studies on organic contrast agents and their future trends demonstrate a greater shift towards contrast agents in the NIR-II window [33,67]. Further studies were detailed in Table 3 with additional studies found in [68–91].
| Classification | Material Used | Imaging Modalities | Application | Studies Conducted | Relevant Measured Parameters | Transducer Used | Computational Techniques | Publication Year/Reference |
|----------------|---------------|--------------------|-------------|------------------|------------------------------|-----------------|---------------------------|-----------------------------|
| Semiconducting Polymer | poly(3-(5-(9-hexyl9-octyl-9H-fluoren-2-yl)thiophen-2-yl)-2,5-bis(2-hexyldecyl)-6-(thiophen-2-yl)pyrrolo[3,4-c]pyrrole-1,4(2H,5H)-dione) (PDPPE, SP0) with SP5 and SP10 (self-quenching SPs) | PAI | Imaging of breast cancer and cervical cancer tumors | HeLa cervical adenocarcinoma epithelial cells for In vitro; In vivo and ex vivo on 4T1 breast cancer tumor in mice/mice organs | Maximum PA signal of SP10 at 4h for both SP10-RGD and SP10 with slower clearance rate for SP10-RGD and 1.78 fold higher PA intensity for SP10-RGD as well | LAZR instrument (Visualsonics, 2100 High-Resolution Imaging System) | - | 2017 [92] |
| Derived from natural resources | DPAHB nanovesicles (hypocrellin B (HB) modified with 1,2-diamino-2-methyl propane encapsulated by PLGA-PEG) | PAI, fluorescence, photodynamic and photothermal therapy | Imaging of 4T1 breast cancer tumors | In vitro and in vivo PAI. | High-intensity signals and enhanced spatial resolution was achieved using DPAHB nanovesicles. PA signal intensity attained maximum peak at 12 h after injection of nanovesicles. | MSOT inVision 128 PAT system | - | 2018 [93] |
| Other | | | | | | | | 2018 [51] 2017 [52,54] 2015 [53] |
| Carbon nanodots | Nitrogen-Doped Carbon Nanodots | PAI | Imaging of sentinel lymph node to detect metastatic cancer | In vivo and ex vivo mapping of sentinel lymph node, in vivo PAI of the bladder. | Post injecting N-CNDs PA signal reached a peak at 30 min, and the signal kept decreasing until 180 min. Results show that the contrast agent was circulating in the lymphatic system before being degraded. | Ultrasound transducer with spherical focusing and having a 5-MHz central frequency, Acoustic-resolution reflection-mode PA imaging system | Raster scanning to acquire PA images | 2016 [94] |
| Classification          | Material Used                                                                 | Imaging Modalities | Application                                                                 | Studies Conducted          | Relevant Measured Parameters                                                                 | Transducer Used | Computational Techniques                                                                 | Publication Year/Reference |
|------------------------|-------------------------------------------------------------------------------|--------------------|------------------------------------------------------------------------------|---------------------------|-----------------------------------------------------------------------------------------------|------------------|-------------------------------------------------------------------------------------------|----------------------------|
| Organic small molecule | Diradicaloid molecular (DRM) structure                                         | PAI and PTT        | Imaging of A549 lung cancer                                                  | PAI-guided PTT in vitro and in vivo | The average PA signal of tumors excised from the mice injected with DRM NPs is over 4 times higher than that from the control group | Vevo LAZR-X imaging equipment | DFT calculations of optimized geometries of the DRM in the ground and excited states | 2021 [95]                 |
| Mitochondria-targeted BODIPY NPs | BODIPY NPs with a cationic triphenylphosphine (TPP) group (Mito-BDP1–5 NPs) bearing different lengths of ethylene glycol (0–4 units), along with HO-BDP5 without a cationic TPP group | PAI and PTI        | Imaging of mitochondria in HeLa cells                                        | In vitro mitochondrial imaging, and in vivo PTI and PAI | Mito-BDP5 possessed high photothermal conversion efficiency (η) of 76.6%, and was able to accumulate in the tumor sites through the EPR effect, subsequently strong PT and PA signals can be observed in tumor sites. | PAI was conducted on a PA computed-tomography system equipped with a 10 MHz, 10 mJ cm$^{-2}$, 384-element ring ultrasound array, and a tunable pulsed laser | -                                                                         | 2021 [96]                 |
| Carbon nanohorns       | carbon nanohorn-polyglycerol-gold (CNH-PG-Au) NPs                            | PAI and x-ray       | Imaging of 4T1 mouse breast cancer cells                                    | In vivo PAI of tumor treatment using DOX@CNH-PG-Au | The photoacoustic intensity of the tumor site increased gradually and reached a maximum 48 h post-injection (735 ± 47), indicating that DOX@CNH-PG-Au NPs steadily accumulated in the tumor during this period | MSOT inVision 256 PAI systems | -                                                                         | 2021 [97]                 |
| Laponite (LAP) nanoplatforms | polydopamine (PDA) coated LAP nanoplatforms modified with polyethylene glycol-arginine-glycine-aspartic acid (PEG-RGD) | PAI                | Imaging of 4T1 mouse breast cancer cells                                    | In vitro and in vivo PAI-guided chemophototherapy of cancer cells | NPs showed an increased PA signal at tumor sites after injection, and the PA signal peaked at 2 h post-injection. | Vevo LAZR PAI system equipped with an 875 nm laser | -                                                                         | 2021 [98]                 |
2.3. Metal/Inorganic Contrast Agents

Metals such as gold and silver significantly enhance contrast in PAI as their optical absorbance is based on surface plasmon resonance (SPR). Therefore, these structures exhibit higher absorbance than other optical agents such as dyes [26]. Metallic agents can also serve as contrast agents in multiple imaging modalities, and so can inorganic nanoparticles. There is increasing interest in using inorganic contrast agents as desirable properties such as tunable peaks in the NIR regions, better brightness, superior photostability, and magnetic and optical scattering and absorption, along with luminescence, renders them useful for multimodal imaging purposes [99]. Ma et al. [14] also synthesized a biocompatible nanosystem that conjugated PEGylated gold nanorods to oligopeptides PT6 and PT7, termed PGNR-PT6 and PGNR-PT7, respectively. These actively targeted nanosystems exhibited an absorbance peak at 810 nm and a high specificity towards osteosarcoma in UMR-106 tumor-bearing mice. Furthermore, a remarkable 2.6- and 3.4-fold contrast from PGNR-PT6 and PGNR-PT7, respectively, was found compared to a PBS-administered control group. Due to the reasons mentioned above and their low cytotoxicity, these nanorods have a strong potential for osteosarcoma-PAI applications. Another study conducted by Li et al. [15] incorporated a liquid perfluorocarbon (perfluorinated hexane/PFH), used as a contrast agent in cancer biomedicine, and gold nanorods, used in PAI due to its strong light absorption in the NIR window, with the nanoemulsion encapsulated in a poly(lactide-co-glycolide) (PLGA) shell. This highly biocompatible shell was then conjugated to a monoclonal MAGE-1 antibody to target melanoma cancer therapy specifically by binding to melanoma antigens. This nanosystem (MAGE-Au-PFH-NP) can be used in dual-modality contrast agents for PA and US imaging. With an encapsulation efficiency of 70.61%, the MAGE-Au-PFH-NPs showed an enhanced PA signal and a linear increase in absorption intensity and concentration. In vivo experiments using melanoma-bearing mice demonstrated peak PA signals after 2 h of injection and a liquid-gas phase transformation after laser irradiation to form microbubbles, functioning as efficient US contrast agents, with a final temperature increase to 70 °C (of the gold nanorods), leading to a PFH phase change. The US signals reached peak values 10 min after laser irradiation and therefore, this nanosystem is a suitable contrast and treatment agent for melanomas. While gold-based contrast agents are a popular choice in PAs, it has several drawbacks, including photoinstability and difficulty in synthesis at the nanoscale [100].

Due to the high optical absorption coefficient of blood in the NIR window, researchers explored the use of magnetic nanoparticles (MNPs) as PA contrast agents, where the magnets’ motion directly influences signal intensity, leading to high contrast images with suppressed images background signals [100,101]. Chau et al. [102] reviewed magnetic molecular imaging and targeting for carbon nanomaterials. They reported that prior to 2015, researchers were functionalizing carbon nanotubes, plated with gold, with proteins for targeting and iron oxide cores for magnetic manipulation. Yang et al. [103] employed the magnetic properties of metals for the trimodal imaging (PET/MRI/PAI) of tumor tissue. Apoferritin, an unloaded natural iron protein with a cage-like structure and transferrin receptor 1 (TfR1) targeting ability, was loaded with melanin nanoparticles (AMF), 64Cu2+ and Fe3+ to image HT29, high TfR1 expression, and HepG2, low TfR1 expression, in tumor-bearing mice. Not only were AMF NPs found to be well suited to the PET and MRI imaging modalities, but the PA signal was twice that of the controls used in the HT29 mouse model. Due to the low TfR1 expression in the HEPG2 mice models, there was no obvious contrast observed. To enable the clinical translation of MNPs to the field of PAI Li et al. [100] not only synthesized a MNP with a functionalized folic acid PEGylated polypyrrole (PPy) shell by polymerizing PPy on the MNP surface to target cervical tumors in a mouse model, but also developed a second-generation magento-motive PAI (mmPAI) system to reduce background noise produced from static and moving tissue incorporating cyclic magnetic motion and US speckle tracking (see Figure 4). A major point of interest in this study was that since conventional PAI cannot easily distinguish a tumor unless there is already prior knowledge of the tumor location, mmPAI was employed to improve
the contrast by two orders of magnitude compared to conventional PA images. This imaging technique can detect 100 to 100,000 tumor cells, whereas current technology has the ability to detect tumor sizes in the mm$^3$ to cm$^3$ range [100]. Other groups such as Wu et al. [104] and Chang et al. [105] have also utilized the magnetic properties of metals, gadolinium/bismuth, and manganese tungsten oxide, respectively, to provide simultaneous multimodal imaging and therapy for oncological purposes (see Table 2). Additionally, studies using low-frequency range PAI to track metallic nanoparticles and their aggregates, in this case, silver nanoparticles and zinc oxide, are available and can be further used to monitor individual scattering and absorption, specifically in the presence of multiple contrast agents [106,107].

The advent of theranostics, the combination of diagnostics and therapeutics, led to the development of several nanoparticles that functioned both as multimodal imaging agents and had a therapeutic function. Hence, novel nanosystems, based on previously well-researched agents, were resynthesized, incorporating desirable characteristics to produce optimal nanosystems suitable for theranostics. Challenges such as complex synthesis routes, decreased biocompatibility, and high instability became an issue [108]. Gold nanoparticles, among the most widely researched and promising exogenous contrast agents [109], were synthesized as gold nanoclusters with strands of polyallylamine and their surface-functionalized with bovine serum albumin (BSA) to serve as diagnostic in vivo PA contrast agents as well as hyperthermic-anticancer agents—for 4T1 tumor-bearing mice [110]. A study using ultra-small Cu$_2$ZnSnS$_4$ (CZTS) nanocrystals functionalized with BSA combined the high NIR photothermal ability of the crystals to simultaneous provide photothermal therapy (PTT), along with dual PA/MRI for in vivo H22 liver tumor-bearing mice where the accumulation of the nanosystem and therefore, the signal intensity was found adequate for image-guided tumor therapy [108]. Antimony (Sb) was mentioned by Li et al. [111] as a potential contrast agent in the field of PAI, and it was further researched by Hou et al. [112] by preparing an oleylamine coated Copper-Antimony- Sulfur (Cu-Sb-S) nanoparticle func-
tionalized with poly(vinylpyrrolidone) (PVP) to act as a PA contrast agent and for use in PTT/photodynamic therapy (PDT). Hong et al. [113] demonstrated that PEGylated melanin dots loaded with gadolinium could serve as effective tumor contrast agents in MRI, and later the same group investigated this agent in vivo [114]. Additional studies were conducted in [75–77,79,110,115–122] (2018), [114,123–126] (2017), [127–133] (2016), [111,134–136] (2015) with further detailed studies summarized and classified in Table 4. In addition, Figure 5 depicts an example of the role contrast agents play in indicating tumor sites.

2.4. Dye-Based Contrast Agents

Studies have shown the ability of some exogenous dyes to absorb NIR light and produce high-intensity PA signals leading to enhanced image contrast [74,115,137,138] (2018); [85,139–141] (2017); [142–147] (2016); [80,88,148–153] (2015). One of the most commonly used dyes is indocyanine green (ICG) that is FDA approved. ICG is typically used in combination with other materials to attain a maximum PA signal. G. Wang et al. [142] used a nanocomplex consisting of hyaluronic acid and ICG enclosed within a nanotube of carbon to detect squamous cell carcinoma in mice. J. Chen et al. [143] detected Hela xenografts in mice using contrast agents made of ICG, polyethylene and nano-graphene oxide. The results showed that the composite could target the tumor passively and had a prolonged circulation time. Gao et al. [144] combined ICG with superparamagnetic iron oxide for the in vivo detection of tumor imaging brain vasculature. In addition to ICG, other dyes such as NIR dyes (IR-825) [85,148], the black hole quencher (BHQ) dye [139], and DiR fluorescent dyes [145] have been used extensively for PAI. A detailed description of dye-based contrast agents and their application are listed in Table 5.

Figure 5. An example of the role contrast agents play in indicating tumor sites, with red representing oxyhemoglobin, blue representing deoxy-hemoglobin, and blue and green representing contrast agents [116].
Table 4. Classification and Summary of Tumor-Targeting In Vivo Studies for PAI Metal-based/Inorganic Contrast Agents.

| Classification | Material Used | Imaging Modalities | Application | Studies Conducted | Relevant Measured Parameters | Transducer Used | Computational Techniques | Publication Year/Reference |
|----------------|---------------|--------------------|-------------|-------------------|----------------------------|----------------|-------------------------|---------------------------|
| Gold nanorods  | AuNR          | PAI                | Imaging of lymph vessels/nodes in breast cancer tumors | Phantom using PTFE tubes; in vivo on mice | Attenuation coefficient: $-1.90 \, \text{dB/mm}$ 380 times as compared ICG | Concave poly(vinylidene fluoride/trifluoroethylene) (P(VDF-TrFE)) US transducer | Delay-and-sum (DAS) beamforming method | 2018 [154] |
| (AuNR)-based   | $^{89}$Zr-labeled bGNR@MSN(DOX)-PEG (Zirconium labeled PEGylated gold nanorods, GNR, coated with mesoporous silica nanoshell) | PAI, PET, PTT and chemotherapy | Imaging of 4T1 breast cancer tumors | In vitro and in vivo on mice | NP diameter: 135.9 nm; 4.7 fold stronger signal from PAI 24 h post-injection as compared to pre-injection | VEVO LAZR PA imaging system | - | 2018 [155] |
| AuNR coated with CTAB. | PAI, US | Imaging of tumor metastases in mice | Imaging of lymph node metastases and tumor mass | In vivo EGFR-targeted PAI of lymph node metastases and tumor mass | Enhanced PA signal observed after 24 h in lymph node with metastases post-injection. | LZ-550 linear array transducer, Vevo 2100 LAZR high-frequency US and PA imaging system. | - | 2016 [127] |
| Gold nanoparticles | PAI, US | Imaging of micro-metastases in lymph nodes | Imaging of lymph node. | High spatial resolution images of micro-metastases (50 µm) were obtained after 2 h of peritumoral injection. | LZ-550 linear array transducer, Vevo LAZR high-frequency US and PA imaging system. | Spectral unmixing, sPA imaging algorithm to differentiate several optical absorbers. | 2014 [156] |
| Furin-cleavable RVRR (Arg-Val-Arg-Arg) peptides (Au-RRVR NPs) | PAI, PTT | Imaging HCT 116 colorectal carcinomas | In vitro and in vivo imaging of tumors | The PA signal reached an intensity maximum of approximately 8 h post-injection with a 1.6-fold enhancement compared to the initial background. | A multispectral optoacoustic tomography scanner with excitation light of 680–900 nm | Maynard operation sequence technique (MOST) measurement | 2021 [157] |
| Classification          | Material Used                                                                 | Imaging Modalities | Application                          | Studies Conducted                                                                 | Relevant Measured Parameters                                                                 | Transducer Used                  | Computational Techniques | Publication Year/Reference |
|------------------------|-------------------------------------------------------------------------------|--------------------|--------------------------------------|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|----------------------------------|--------------------------|--------------------------|
| **Gadolinium-/bismuth-based** | Gd-PEG-Bi NPs (hydrophobic dodecanethiol-Bi nanoparticles, for CT and PA contrast, coated in gadolinium, for MRI, and PEG) | PAI, CT, MRI and for PTT | Imaging of C6 glial tumors          | In vitro and in vivo on mice; hemolysis assay and in vivo blood clearance and bio-distribution | NP diameter: 45 nm; Strong PA signals at low concentrations of 0.625 mg/mL and after 30 min; Strongest PA signal at 3 h and blood half-life at 4.69 h; High biosafety and NIR absorption coefficient | Endra Nexus 128 PA imaging system | -                        | 2018 [104]               |
| **Manganese-based**    | GO/MnWO4/PEG/DOX (Graphene-oxide, GO, grown in situ onto manganese tungsten oxide in the presence of PEG and loaded with doxorubicin) | PAI, MRI, PTT and chemotherapy | Imaging of breast cancer tumors (4T1 mouse mammary carcinoma) | In vitro and in vivo on mice; PTT, chemotherapy and cytotoxicity | Maximum PA signal observed at tumor region 6 h post-injection in vivo; however, the signal was maintained at 1.4 times that of pre-injection at 24 h. Little to no cytotoxicity observed | MOST inVision128, iThera Medical | -                        | 2018 [105]               |
| **Iron oxide-based**   | Magnetic iron oxide nanoparticles                                                 | Molecular PAT      | Imaging of 4T1 breast cancer tumors | In vivo molecular photoacoustic tomography of breast cancer in mice                  | Post injection of contrast agents PA signal increased 3 times after 5 min and 10 times after 24 h. | Focused-ultrasound transducer operating at 50 MHz and 3.5 MHz | Raster scanning to acquire PA images, Hilbert transform was used to process acquired signals. | 2014 [158]               |
| **Copper(II) sulfide nanoparticles (CuS)** | Copper(II) chloride, sodium sulfide, methoxy-PEG-thiol to form polyethylene glycol (PEG)-coated copper(II) sulfide nanoparticles | PAT                | Imaging of 4T1 breast cancer tumors | In vivo PAT of blood vasculature of 4T1 breast cancer in mouse                     | After 2 h and 5 min of injecting contrast agent, PA signal had maximum intensity and minute details of blood vessels at tumor site were shown with great clarity. | -                                | -                        | 2014 [159]               |
| Classification | Material Used | Imaging Modalities | Application | Studies Conducted | Relevant Measured Parameters | Transducer Used | Computational Techniques | Publication Year/Reference |
|----------------|---------------|--------------------|-------------|------------------|----------------------------|-----------------|--------------------------|---------------------------|
| ICG-based      | ICG           | PAI                | Imaging of lymph vessels/nodes in breast cancer tumors | Phantom using PTFE tubes; in vivo on mice | Attenuation coefficient: $-1.90 \text{ dB/mm}$ | Concave poly(vinylidenefluoride/trifluoroethylene) (PVDF-TrFE) US transducer | Delay-and-sum (DAS) beamforming method | 2018 [154] |
|                | ICG-cRGD      | PAI                | Imaging of human glioblastoma (U-87MG, high $\alpha \beta 3$ expression) and epidermoid carcinoma (A431, low $\alpha \beta 3$ expression) | In vitro and in vivo on mice; followed by ex vivo of mice organs | Signal: plateaued after 30–60 min for ICG-RGD in U-87 MG and sustained for 24 h post-injection; 25 times greater for U-97MG than for A431 | Vevo LAZR LZ250 PA imaging system | Spectral unmixing | 2018 [17] |
| SDF-1/ICG/PFH/DOX PLGA NPs (PLGA shells encapsulating PFH, Doxorubicin and ICG and conjugated to chemokine SDF-1) | PAI, PTT and chemotherapy | Imaging of metastatic lymph nodes in tongue squamous cell carcinoma | In vitro and in vivo on rabbits | Signal: plateaued at 1 h and was sustained for 24 h post-injection; higher signal intensity for targeted groups than for non-targeted control | VEVO LAZR PA imaging system | - | 2019 [160] |
| Sodium hyaluronic acid, Ethylenediamine, ICG, single-walled carbon nanotubes | PAI | In vivo Imaging of SCC7 Tumor in mice | In vivo and ex vivo on mice | PA signal was not clear with the injection of free ICG. ICG combined with hyaluronic acid nanoparticles in SWCNT encapsulation provided strong signals. Image contrast decreased after 48 h of injecting IHANPT. | Endra Nexus128 imaging system | - | 2016 [89] |
| Classification                  | Material Used                                                                 | Imaging Modalities     | Application                                                                 | Studies Conducted                                                                 | Relevant Measured Parameters                                                                 | Transducer Used                                                                 | Computational Techniques                                                                 | Publication Year/Reference |
|--------------------------------|--------------------------------------------------------------------------------|------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------------|
| ICG, polyethylene glycol, reduced Nano-graphene oxide composite | PAI, Fluorescence imaging                                                      | In vivo imaging of Hela tumor (cervical carcinoma) models in mice         | PAI of Phantoms, In Vivo PAI, In Vivo Toxicity Assessment                         | Nanocomposite produced minimal toxicity. Blood circulation time was 6 h. PAI showed accumulation and distribution of injected contrast agents at the tumor site. | Olympus focused ultrasound transducer with a central frequency of 10 MHz. Acoustic-resolution photoacoustic microscopy system | -                                                              |                                                                              | 2016 [149] |

| Squaraine dye nanoprobe        | squaraine dye SQ1 constructed from ethyl-grafted 1,8-naphtholactam and square acid in a donor-acceptor-donor structure | PAI, fluorescence imaging and PTT                                        | PAI of breast cancer cells (MDA-MB-231 and MCF-7)                              | In vitro and in vivo imaging                                                          | SQ1nanoprobe performed well in both PA imaging and PTT of solid tumors. PA images and corresponding PA intensities at 930 nm were obtained by a PA microscopy system | -                                                              |                                                                              | 2020 [161] |
2.5. Biosensors and Nanoprobes for In Vivo Tumor Studies

Since sensitivity and selectivity are vital for the early detection of cancer metastases, researchers have developed probes that react with molecules that have major functional roles in pathology—mainly in tumor growth. Such materials have been developed for other imaging modalities such as fluorescence imaging [162], PET, MRI, computed tomography (CT), and echography [163] and tested in vivo on tumor-bearing mice. PAI nanoprobes can detect cancer-associated growth on a molecular level and help clinicians administer precise dosage amounts to cancer patients, thus decreasing the adverse side effects of conventional chemotherapy. One such probe was developed by Wang et al. [78], where elevated nitric oxide levels, a characteristic of tumor sites, would lead to a linear increase in PA signal based on concentration levels. This probe was composed of benzothiadiazole conjugated to diphenylamine on both ends in a donor-acceptor-donor conformation. Chen et al. [146] used a novel approach to synthesize a pH-sensitive probe that performed the dual action of changing the PA signal intensity based on pH in the microenvironment, with increased signal in acidic environments, as well as performing photothermal action by self-assembly of human serum albumin and croconine-dye nanoparticles to eliminate tumor cells. The same research group used this probe to detect changes in tumor acidity by developing a metal, calcium ion and organic ligand, dicarboxylic cisplatin prodrug, nanoparticles covered with poly-l-histidine-PEG (pHis-PEG) to oxidize H$_2$O$_2$ and thus, perform dual-cancer therapy and real-time in vivo imaging [164].

There are a limited number of studies in the biosensor field, including PAI. This could be attributed to the tedious process of validating biosensors to determine whether they are clinically applicable and safe for use [165]. Since the interaction between the probe molecule and the target molecule should be highly selective, i.e., it should not respond adversely to other components in vivo, specifically, if other benign diseases exhibit increased concentrations of the target molecule. The reproducibility and commercialization of these biosensors might contribute to this comparatively unexplored field of probe and biosensor in cancer research. Figure 6 presents a summary of the studies conducted using different types of PAI contrast agents over the past four years.

![Figure 6](image_url)

**Figure 6.** (a) No. of studies in the last four years. (b) Total number of studies in the last four years based on classification.

3. Conclusions, Challenges and Future Directions

PAI is a promising modality for real-time imaging which can be developed by combining the properties of exogenous contrast agents such as metallic, carbon-based, semimetallic, polymer-based nanomaterials and dyes. This review follows and categorizes the development of exogenous contrast agents for in vivo imaging, specifically tumor imaging. Different strategies have been exploited to enhance the PA signal, including incorporating moieties, inducing the plasmon coupling effect, coupling different classes of nanomaterials and dyes, forming stimuli-responsive nanoagents, magnetic and photo-induced electron
transfer for background signal reduction, and self-assembly of materials. Other techniques include improving imaging systems for the synchronized detection of PA signals [166].

The field of optoacoustics/PA has vast implications for clinical translation, with one of the first studies for intraoperative breast cancer surgeries revealing successful tumor margin identification and identification of the biochemical contents. The current state-of-the-art in tumor margin definition is histological analysis, which requires the removal of the tumor and a 24-h period for analysis. The development of PAI implies that the clinical need for fast and real-time processing can finally be met in oncology. With regards to image characteristics, this study showed that PAI used a scan time of 20 min along with satisfactory penetration depths and high-resolution images compared to fluorescence, Raman spectroscopy, and diffuse reflection imaging [167]. Numerous studies revealed promising results [168]; however, extensive cohort studies are still needed before PAI can be used as a state-of-the-art imaging modality in oncology with a future trend towards NIR-II contrast agent development. Future studies may focus on developing more efficient stimuli-responsive agents that track shifts in absorptions peaks based on changes in the tumor microenvironment, while evaluating its toxicity, biocompatibility, biodegradability, and photostability.

Author Contributions: Conceptualization, S.D. and G.H.; methodology, A.F., S.S., S.D., N.A., and G.H.; validation, S.D., N.A., and G.H.; formal analysis, A.F., S.S., and N.A.; investigation, A.F., S.S., and N.A.; resources, S.D.; writing—original draft preparation, A.F. and S.S.; writing—review and editing, S.D., N.A., and G.H.; visualization, A.F., S.S., and N.A.; supervision, S.D. and G.H.; project administration, S.D. and G.H.; funding acquisition, S.D. All authors have read and agreed to the published version of the manuscript.

Funding: The work in this paper was supported, in part, by the Open Access Program from the American University of Sharjah [Award #: OAPCEN-1410-E00025]. This paper represents the opinions of the author(s) and does not mean to represent the position or opinions of the American University of Sharjah.

Acknowledgments: Afifa Farooq, Shafiya Sabah, and Nour Alsawaftah thank the Biomedical Engineering Graduate Program at the American University of Sharjah for funding their graduate studies.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Deán-Ben, X.L.; Gottschalk, S.; McLarney, B.; Shoham, S.; Razansky, D. Advanced optoacoustic methods for multiscale imaging of in vivo dynamics. Chem. Soc. Rev. 2017, 46, 2158–2198. [CrossRef] [PubMed]
2. Liu, Y.; Nie, L.; Chen, X. Photoacoustic molecular imaging: From multiscale biomedical applications towards early-stage theranostics. Trends Biotechnol. 2016, 34, 420–433. [CrossRef] [PubMed]
3. Yao, J.; Wang, L.V. Photoacoustic tomography: Fundamentals, advances and prospects. Contrast Media Mol. Imaging 2011, 6, 332–345. [CrossRef]
4. Sun, Y.; Jiang, H.; O’Neill, B.E. Photoacoustic imaging: An emerging optical modality in diagnostic and theranostic medicine. J. Biosens. Bioelectron. 2011, 2, 3. [CrossRef]
5. Bell, A.G. On the production and reproduction of sound by light. Am. J. Sci. 1880, 29, 305–324. [CrossRef]
6. Esenaliev, R.O.; Karabutov, A.A.; Tittel, F.K.; Fornage, B.D.; Thomsen, S.L.; Stelling, C.; Oraevsky, A.A. Laser optoacoustic imaging for breast cancer diagnostics: Limit of detection and comparison with x-ray and ultrasound imaging. In Optical Tomography and Spectroscopy of Tissue: Theory, Instrumentation, Model, and Human Studies II; International Society for Optics and Photonics: Bellingham, WA, USA, 1997; Volume 2979, pp. 71–83. [CrossRef]
7. Oraevsky, A.A.; Andreev, V.A.; Karabutov, A.A.; Fleming, R.D.; Gatalica, Z.; Singh, H.; Esenaliev, R.O. Laser optoacoustic imaging of the breast: Detection of cancer angiogenesis. In Optical Tomography and Spectroscopy of Tissue III; International Society for Optics and Photonics: Bellingham, WA, USA, 1999; Volume 3597, pp. 352–363. [CrossRef]
8. Oraevsky, A.A.; Jacques, S.L.; Esenaliev, R.O.; Tittel, F.K. Direct measurement of laser fluence distribution and optoacoustic imaging in heterogeneous tissues. In Laser Interaction with Hard and Soft Tissue II; International Society for Optics and Photonics: Bellingham, WA, USA, 1995; Volume 2323, pp. 37–46. [CrossRef]
9. Bertolotti, M.; Voti, R.L. A note on the history of photoacoustic, thermal lensing, and photothermal deflection techniques. J. Appl. Phys. 2020, 128, 230901. [CrossRef]
10. Oraevsky, A.A.; Karabutov, A.A.; Solomatín, S.V.; Savateeva, E.V.; Andreev, V.A.; Gatilova, Z.; Singh, H.; Fleming, R.D. Laser optoacoustic imaging of breast cancer in vivo. In Biomedical Optoacoustics II; International Society for Optics and Photonics: Bellingham, WA, USA, 2001; Volume 4256, pp. 6–15.

11. De Mul, F.F.M.; Pilotau, M.C.; Kolkmann, R.G.M.; Hondebrink, E.; Steenbergen, W. Photoacoustic imaging of blood vessels in tissues. In Laser Florence 2001: A Window on the Laser Medicine World; International Society for Optics and Photonics: Bellingham, WA, USA, 2002; Volume 4903, pp. 208–213.

12. Xavierselvan, M.; Singh, M.K.A.; Mallidi, S. In vivo tumor vascular imaging with light emitting diode-based photoacoustic imaging system. Sensors 2020, 20, 4503. [CrossRef]

13. Hirasawa, T.; Iwatate, R.J.; Kamiya, M.; Okawa, S.; Urano, Y.; Ishihara, M. Multispectral photoacoustic imaging of tumours in mice injected with an enzyme-activatable photoacoustic probe. J. Opt. 2017, 19, 14002. [CrossRef]

14. Ma, Z.M.; Qin, H.P.; Chen, H.M.; Yang, H.; Xu, J.; Yang, S.P.; Hu, J.P.; Xing, D.P. Phage display-derived oligopeptide-functionalized probes for in vivo specific photoacoustic imaging of osteosarcoma. Nanomed. Nanotechnol. Biol. Med. 2017, 13, 111–121. [CrossRef]

15. Li, X.; Wang, D.; Ran, H.; Hao, L.; Cao, Y.; Ao, M.; Zhang, N.; Song, J.; Zhang, L.; Yi, H.; et al. A preliminary study of photoacoustic/ultrasound dual-mode imaging in melanoma using MAGE-targeted gold nanoparticles. Biochem. Biophys. Res. Commun. 2018, 502, 252–261. [CrossRef]

16. Kim, J.-W.; Galanzea, E.I.; Shashkov, E.V.; Moon, H.-M.; Zharov, V.P. Golden carbon nanotubes as multimodal photoacoustic and photothermal high-contrast molecular agents. Nat. Nanotechnol. 2009, 4, 688–694. [CrossRef]

17. Capozza, M.; Blasi, F.; Valbusa, G.; Oliva, P.; Cabella, C.; Buonsanti, F.; Cordaro, A.; Pizzuto, L.; Maiocchi, A.; Poggi, L. Photoacoustic imaging of intact-overexpressing tumors using a novel ICG-based contrast agent in mice. Photoacoustics 2018, 11, 36–45. [CrossRef] [PubMed]

18. de la Zerda, A.; Bodapati, S.; Teed, R.; May, S.Y.; Tabakman, S.M.; Liu, Z.; Khuri-Yakub, B.T.; Chen, X.; Dai, H.; Gambhir, S.S. Family of enhanced photoacoustic imaging agents for high-sensitivity and multiplexing studies in living mice. ACS Nano 2012, 6, 4694–4701. [CrossRef] [PubMed]

19. Zanganah, S.; Li, H.; Kumavor, P.D.; Alqasemi, U.S.; Aguirre, A.; Mohammad, I.; Stanford, C.; Smith, M.B.; Zhu, Q. Photothermal imaging enhanced by indocyanine green-conjugated single-wall carbon nanotubes. J. Biomed. Opt. 2013, 18, 096006. [CrossRef] [PubMed]

20. Lavaud, J.; Henry, M.; Coll, J.-L.; Josserand, V. Exploration of melanoma metastases in mice brains using endogenous contrast photoacoustic imaging. Int. J. Pharm. 2017, 532, 704–709. [CrossRef]

21. Neuwirth, M.; Sinnamon, A.J.; Schultz, S.; Seghal, C.; Xu, G.; Karakousis, G.C. Detection of melanoma metastases in regional lymph nodes using multispectral photoacoustic imaging. J. Am. Coll. Surg. 2017, 225, S189. [CrossRef]

22. Cheng, K.; Cheng, Z. Diagnostic applications. In Acoustic and Photoacoustic Molecular Imaging of Cancer; Fadeel, B., Pietroiusti, A., Shvedova, A.A., Eds.; Elsevier: Amsterdam, The Netherlands, 2012; pp. 265–284.

23. Johnstonbaugh, K.; Agrawal, S.; Durairaj, D.A.; Homewood, M.; Karri, S.P.K.; Kothapalli, S.-R. Novel deep learning architecture for optical fluorescence dependent photoacoustic target localization. In Photons Plus Ultrasound: Imaging and Sensing 2019; International Society for Optics and Photonics: Bellingham, WA, USA, 2019; Volume 10878, p. 108781L.

24. Costa, M.M.; Shah, A.; Rivens, I.; Box, C.; O’Shea, T.; Papaevangelou, E.; Bamber, J.; ter Haar, G. Quantitative photoacoustic imaging study of tumours in vivo: Baseline variations in quantitative measurements. Photoacoustics 2018, 13, 53–65. [CrossRef] [PubMed]

25. Steinberg, I.; Huland, D.M.; Vermesh, O.; Frostig, H.E.; Tummers, W.S.; Gambhir, S.S. Photoacoustic clinical imaging. Photoacoustics 2019, 14, 77–98. [CrossRef]

26. Mehrmohammadi, M.; Yoon, S.J.; Yeager, D.; Emelianov, S. Photoacoustic imaging for cancer detection and staging. Curr. Mol. Imaging 2013, 2, 89–105. [CrossRef] [PubMed]

27. Wilson, K.E.; Wang, T.Y.; Willmann, J.K. Acoustic and photoacoustic molecular imaging of cancer. J. Nucl. Med. 2013, 54, 1851–1854. [CrossRef]

28. Attia, A.B.E.; Bala sundaram, G.; Moothanchery, M.; Dinish, U.; Bi, R.; Nitziachristos, V.; Olivo, M. A review of clinical photoacoustic imaging: Current and future trends. Photoacoustics 2019, 16, 100144. [CrossRef] [PubMed]

29. Zhao, T.; Desjardins, A.E.; Ourselin, S.; Vercauteren, T.; Xia, W. Minimally invasive photoacoustic imaging: Current status and future perspectives. Photoacoustics 2019, 16, 100146. [CrossRef] [PubMed]

30. Vu, T.; Razansky, D.; Yao, J. Listening to tissues with new light: Recent technological advances in photoacoustic imaging. J. Opt. 2019, 21, 103001. [CrossRef] [PubMed]

31. Gargiulo, S.; Albanese, S.; Mancini, M. State-of-the-art preclinical photoacoustic imaging in oncology: Recent advances in cancer theranostics. Contrast Media Mol. Imaging 2019, 2019, 5080267. [CrossRef] [PubMed]

32. Upputuri, P.K.; Pramanik, M. Recent advances in photoacoustic contrast agents for in vivo imaging. WIREs Nanomed. Nanobiotechnol. 2020, 12, e1618. [CrossRef]

33. Zhang, J.; Ning, L.; Zeng, Z.; Pu, K. Development of second near-infrared photoacoustic imaging agents. Trends Chem. 2021, 3, 305–317. [CrossRef]

34. Liu, W.-W.; Li, P.-C. Photoacoustic imaging of cells in a three-dimensional microenvironment. J. Biomed. Sci. 2020, 27, 3. [CrossRef]

35. Siddique, S.; Chow, J.C.L. Application of nanomaterials in biomedical imaging and cancer therapy. Nanomaterials 2020, 10, 1700. [CrossRef]
36. Lusic, H.; Grinstaff, M. X-ray-computed tomography contrast agents. Chem. Rev. 2012, 113, 1641–1666. [CrossRef]
37. Ignee, A.; Atkinson, N.S.; Schuessler, G.; Dietrich, C. Ultrasound contrast agents. Endose. Ultrasound 2016, 5, 355–362. [CrossRef]
38. Kiani, A.; Esquevin, A.; Lepareur, N.; Bourguet, P.; Le Jeune, F.; Gauvrit, J. Main applications of hybrid PET-MRI contrast agents: A review. Contrast Media Mol. Imaging 2015, 11, 92–98. [CrossRef] [PubMed]
39. Criscione, J.M.; Dobrucky, L.W.; Zhuang, Z.W.; Papademetris, X.; Simons, M.; Sinusas, A.J.; Fahmy, T.M. Development and application of a multimodal contrast agent for SPECT/CT hybrid imaging. Bioconjug. Chem. 2011, 22, 1784–1792. [CrossRef] [PubMed]
40. Xia, J.; Yao, J.; Wang, L. Photoacoustic tomography: Principles and advances. Prog. Electromagn. Res. 2014, 147, 1–22. [CrossRef] [PubMed]
41. Zhang, Y.; Hong, H.; Cai, W. Photoacoustic imaging. Cold Spring Harb. Protoc. 2011, 2011, 1015–1025. [CrossRef] [PubMed]
42. Weissleder, R. A clearer vision for in vivo imaging. Nat. Biotechnol. 2001, 19, 316–317. [CrossRef] [PubMed]
43. Lyu, Y.; Li, J.; Pu, K. Second near-infrared absorbing agents for photoacoustic imaging and photothermal therapy. Small Methods 2019, 3, 1900553. [CrossRef]
44. Upputuri, P.K.; Pramanik, M. Photoacoustic imaging in the second near-infrared window: A review. J. Biomed. Opt. 2019, 24, 040901. [CrossRef]
45. Hoshyar, N.; Gray, S.; Han, H.; Bao, G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine 2016, 11, 673–692. [CrossRef]
46. Sharma, A.; Jain, N.; Sareen, R. Nanocarriers for diagnosis and targeting of breast cancer. BioMed. Res. Int. 2013, 2013, 960821. [CrossRef]
47. Holowka, E.P.; Bhatia, S.K. Drug Delivery: Materials Design and Clinical Perspective; Springer: New York, NY, USA, 2014; ISBN 9781493919987.
48. Yoo, J.-W.; Doshi, N.; Mitragotri, S. Adaptive micro and nanoparticles: Temporal control over carrier properties to facilitate drug delivery. Adv. Drug Deliv. Rev. 2011, 63, 1247–1256. [CrossRef]
49. Li, K.; Liu, B. Polymer-encapsulated organic nanoparticles for fluorescence and photoacoustic imaging. Chem. Soc. Rev. 2014, 43, 6570–6597. [CrossRef] [PubMed]
50. Xiao, W.; Li, Y.; Hu, C.; Huang, Y.; He, Q.; Gao, H. Melanin-originated carbonaceous dots for triple negative breast cancer diagnosis by fluorescence and photoacoustic dual-mode imaging. J. Colloid Interface Sci. 2017, 497, 226–232. [CrossRef] [PubMed]
51. Jia, Q.; Zheng, X.; Ge, J.; Liu, W.; Ren, H.; Chen, S.; Wen, Y.; Zhang, H.; Wu, J.; Wang, P. Synthesis of carbon dots from Hypocrella bambusae for bimodal fluorescence/photoacoustic imaging-guided synergistic photodynamic/photothermal therapy of cancer. J. Colloid Interface Sci. 2018, 526, 302–311. [CrossRef] [PubMed]
52. Parvin, N.; Mandal, T.K. Dually emissive PN-co-doped carbon dots for fluorescent and photoacoustic tissue imaging in living mice. Microchim. Acta 2017, 184, 1107–1125. [CrossRef]
53. Ge, J.; Jia, Q.; Liu, W.; Guo, L.; Liu, Q.; Lan, M.; Zhang, H.; Meng, X.; Wang, P. Red-emissive carbon dots for fluorescent, photoacoustic, and thermal theranostics in living mice. Adv. Mater. 2015, 27, 4169–4177. [CrossRef] [PubMed]
54. Chen, Q.; Liang, C.; Sun, X.; Chen, J.; Yang, Z.; Zhao, H.; Feng, L.; Liu, Z. H2O2-responsive liposomal nanoprobe for photoacoustic inflammation imaging and tumor theranostics via in vivo chromogenic assay. Proc. Natl. Acad. Sci. USA 2017, 114, 5343–5348. [CrossRef] [PubMed]
55. Zhang, R.; Feng, L.; Dong, Z.; Wang, L.; Liang, C.; Chen, J.; Ma, Q.; Chen, Q.; Wang, Y.; Liu, Z. Glucose and oxygen exhausting liposomes for combined cancer starvation and hypoxia-activated therapy. Biomaterials 2018, 162, 123–131. [CrossRef]
56. Liu, K.; Wang, X.; Nitziaristos, V.; Marsch, S.; Hunziker, P. Polymeric nanosystems for near-infrared multispectral photoacoustic imaging: Synthesis, characterization and in vivo evaluation. Eur. Polym. J. 2017, 88, 713–723. [CrossRef]
57. AlSawaftah, N.; Pitt, W.G.; Hussein, G.A. Dual-targeting and stimuli-triggered liposomal drug delivery in cancer treatment. ACS Pharmacol. Transl. Sci. 2021, 4, 1028–1049. [CrossRef]
58. Neumann, P.R.; Erdmann, F.; Holthof, J.; Hädrich, G.; Green, M.; Rao, J.; Dailey, L.A. Different PEG-PLGA matrices influence in vivo optical/photoacoustic imaging performance and biodistribution of NIR-emitting π-conjugated polymer contrast agents. Adv. Health Mater. 2020, 9, 2001089. [CrossRef]
59. Abelha, T.F.; Dreiss, C.A.; Green, M.A.; Dailey, L.A. Conjugated polymers as nanoparticle probes for fluorescence and photoacoustic imaging. J. Mater. Chem. B 2020, 8, 592–606. [CrossRef] [PubMed]
60. Kim, H.; Lee, H.; Moon, H.; Kang, J.; Jang, Y.; Kim, D.; Kim, J.; Huynh, E.; Zheng, G.; Kim, H.; et al. Resonance-based frequency-selective amplification for increased photoacoustic imaging sensitivity. ACS Photon. 2019, 6, 2268–2276. [CrossRef]
61. Li, C.; Liu, C.; Fan, Y.; Ma, X.; Zhan, Y.; Lu, X.; Sun, Y. Recent development of near-infrared photoacoustic probes based on small-molecule organic dye. RSC Chem. Biol. 2021, 2, 743–758. [CrossRef] [PubMed]
62. Paproski, R.J.; Forbrich, A.; Huynh, E.; Chen, J.; Lewis, J.D.; Zheng, G.; Zemp, R.J. Porphyrin nanodroplets: Sub-micrometer ultrasound and photoacoustic contrast imaging agents. Small 2016, 12, 371–380. [CrossRef] [PubMed]
63. Gao, D.; Zhang, B.; Liu, Y.; Hu, D.; Sheng, Z.; Zhang, X.; Yuan, Z. Molecular engineering of near-infrared light-responsive BODIPY-based nanoparticles with enhanced photothermal and photoacoustic efficiencies for cancer theranostics. Theranostics 2019, 9, 5315–5331.
64. Wang, Z.; Upputuri, P.K.; Zhen, X.; Zhang, R.; Jiang, Y.; Ai, X.; Zhang, Z.; Hu, M.; Meng, Z.; Lu, Y.; et al. pH-sensitive and biodegradable charge-transfer nanocomplex for second near-infrared photoacoustic tumor imaging. *Nano Res.* 2019, 12, 49–55. [CrossRef]

65. Miao, Q.; Lyu, Y.; Ding, D.; Pu, K. Semiconducting oligomer nanoparticles as an activatable photoacoustic probe with amplified brightness for in vivo imaging of pH. *Adv. Mater.* 2016, 28, 3662–3668. [CrossRef]

66. Dragulescu-Andrasi, A.; Kothapalli, S.-R.; Tikhomirov, G.; Rao, J.; Gambhir, S.S. Activatable oligomerizable imaging agents for photoacoustic imaging of furin-like activity in living subjects. *J. Am. Chem. Soc.* 2013, 135, 11015–11022. [CrossRef]

67. Jung, D.; Park, S.; Lee, C.; Kim, H. Recent progress on near-infrared photoacoustic imaging: Imaging modality and organic semiconducting agents. *Polymers* 2019, 11, 1693. [CrossRef]

68. Bharathiraja, S.; Manivasagan, P.; Moorthy, M.S.; Bui, N.Q.; Jang, B.; Phan, T.T.V.; Jung, W.-K.; Kim, Y.-M.; Lee, K.D.; Oh, J. Photo-featured PDT/PTT dual model killing and imaging of cancer cells using phycocyanin-polypyrrole nanoparticles. *Eur. J. Pharm. Biopharm.* 2017, 123, 20–30. [CrossRef]

69. Guo, Y.; Wang, X.-Y.; Chen, Y.-L.; Liu, F-Q.; Tan, M.-X.; Ao, M.; Yu, J.-H.; Ran, H.-T.; Wang, Z.-X.; Guo, Y.; et al. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy. *Acta Biomater.* 2018, 80, 308–326. [CrossRef] [PubMed]

70. Mattu, C.; Brachi, G.; Menichetti, L.; Flori, A.; Armanetti, P.; Ranzato, E.; Martinotti, S.; Nizzero, S.; Ferrari, M.; Ciardelli, G. Alternating Block Copolymer-Based Nanoparticles as Tools to Modulate the Loading of Multiple Chemotherapeutics and Imaging Probes. *Acta Biomater.* 2018, 80, 341–351. [CrossRef] [PubMed]

71. Xiao, W.; Yang, P.; Ou, C.; Huang, X.; Tang, Y.; Wu, M.; Si, W.; Shao, J.; Huang, W.; Dong, X. 2-Pyridone-Functionalized Aza-BODIPY Photosensitizer for Imaging-Guided Sustainable Phototherapy. *Biomaterials* 2018, 183, 1–9. [CrossRef] [PubMed]

72. Sheng, D.; Liu, T.; Deng, L.; Zhang, L.; Li, X.; Xu, J.; Hao, L.; Li, P.; Ran, H.; Chen, H.; et al. Perfluoroacetyl Bromide & Indocyanine Green Co-Loaded Nanoliposomes for Enhanced Multimodal Imaging-Guided Phototherapy. *Biomaterials* 2018, 165, 1–13. [CrossRef]

73. Wang, F.; Huang, Q.; Wang, Y.; Shi, L.; Shen, Y.; Guo, S. NIR-Light and GSH Activated Cytosolic P65-ShRNA Delivery for Precise Treatment of Metastatic Cancer. *J. Control. Release* 2018, 288, 126–135. [CrossRef]

74. Deng, L.; Xu, Y.; Sun, C.; Yun, B.; Sun, Q.; Zhao, C.; Li, Z. Functionalization of Small Black Phosphorus Nanoparticles for Targeted Imaging and Photothermal Therapy of Cancer. *Sci. Bull.* 2018, 63, 917–924. [CrossRef]

75. Weng, Y.; Guan, S.; Lu, H.; Meng, X.; Kaassiss, A.Y.; Ren, X.; Qu, X.; Sun, C.; Xie, Z.; Zhou, S. Confinement of Carbon Dots Localizing to the Ultrathin Layered Double Hydroxides toward Simultaneous Triple-Mode Bioimaging and Photothermal Therapy. *Talanta* 2018, 184, 50–57. [CrossRef] [PubMed]

76. Cheng, Y.; Tan, X.; Wang, J.; Wang, Y.; Song, Y.; You, Q.; Sun, Q.; Liu, L.; Wang, S.; Tan, F.; et al. Polymer-Based Gadolinium Oxide Nanocomposites for FL/MR/PA Imaging Guided and Photothermal/Photodynamic Combined Anti-Tumor Therapy. *J. Control. Release* 2018, 277, 78–88. [CrossRef]

77. Wang, F.; Huang, Q.; Wang, Y.; Zhang, W.; Lin, R.; Yu, Y.; Shen, Y.; Cui, H.; Guo, S. Rational Design of Multimodal Therapeutic Nanosystems for Effective Inhibition of Tumor Growth and Metastasis. *Acta Biomater.* 2018, 77, 240–254. [CrossRef]

78. Wang, S.; Li, Z.; Liu, Y.; Feng, G.; Zheng, J.; Yuan, Z.; Zhang, X. Activatable Photoacoustic and Fluorescent Probe of Nitric Oxide for Cellular and in Vivo Imaging. *Sens. Actuators B Chem.* 2018, 267, 403–411. [CrossRef]

79. Lin, G.; Zhang, Y.; Zhu, C.; Chu, C.; Shi, Y.; Pang, X.; Ren, E.; Wu, Y.; Mi, P.; Xia, H.; et al. Photo-excitatable hybrid nanocomposites for image-guided photo/thermal cancer therapy. *Biomaterials* 2018, 176, 60–70. [CrossRef] [PubMed]

80. Su, Y.Y.; Yao, H.; Zhao, S.; Tian, W.; Liu, W.F.; Wang, S.; Liu, Y.; Tian, Y.; Zhang, X.D.; Teng, Z.G.; et al. Ag-HPBs by a coating-etching strategy and their derived injectable implants for enhanced tumor photothermal treatment. *J. Colloid Interface Sci.* 2018, 512, 439–445. [CrossRef] [PubMed]

81. Chen, H.; Zhang, J.; Chang, K.; Men, X.; Fang, X.; Zhou, L.; Li, D.; Gao, D.; Yin, S.; Zhang, X.; et al. Highly absorbing multispectral near-infrared polymer nanoparticles from one conjugated backbone for photothermal imaging and photothermal therapy. *Biomaterials* 2017, 144, 42–52. [CrossRef]

82. Jiang, Y.; Cui, D.; Fang, Y.; Zhen, X.; Upputuri, P.K.; Pramanik, M.; Ding, D.; Pu, K. Amphiphilic semiconducting polymer as multifunctional nanocarrier for fluorescence/photoacoustic imaging guided chemo-photothermal therapy. *Biomaterials* 2017, 145, 168–177. [CrossRef] [PubMed]

83. Li, Y.; Jiang, C.; Zhang, D.; Wang, Y.; Ren, X.; Ai, K.; Chen, X.; Lu, L. Targeted polydopamine nanoparticles enable photoacoustic imaging guided chemo-photothermal synergistic therapy of tumor. *Acta Biomater.* 2016, 47, 124–134. [CrossRef] [PubMed]

84. Jin, Y.; Ma, X.; Zhang, S.; Meng, H.; Xu, M.; Yang, X.; Xu, W.; Tian, J. A tantalum oxide-based core/shell nanoparticle for triple-modality image-guided chemo-thermal synergistic therapy of esophageal carcinoma. *Cancer Lett.* 2017, 397, 61–71. [CrossRef]

85. Liang, X.; Fang, L.; Li, X.; Zhang, X.; Wang, F. Activatable near infrared dye conjugated hyaluronic acid-based nanoparticles as a targeted theranostic agent for enhanced fluorescence/CT/photoacoustic imaging guided photothermal therapy. *Biomaterials* 2017, 132, 72–84. [CrossRef]

86. Hu, D.; Sheng, Z.; Gao, G.; Siu, F.; Liu, C.; Wan, Q.; Gong, P.; Zheng, H.; Ma, Y.; Cai, L. Activatable albumin-photosensitizer nanoassemblies for triple-modal imaging and thermal-modulated photodynamic therapy of cancer. *Biomaterials* 2016, 93, 10–19. [CrossRef]
87. Li, W.; Zheng, C.; Pan, Z.; Chen, C.; Hu, D.; Gao, G.; Kang, S.; Cui, H.; Gong, P.; Cai, I. Smart hyaluronidase-activated theranostic micelles for dual-modal imaging guided photodynamic therapy. *Biomaterials* 2016, 101, 10–19. [CrossRef]

88. Xie, L.; Wang, G.; Zhou, H.; Zhang, F.; Guo, Z.; Liu, C.; Zhang, X.; Zhu, L. Functional long circulating single walled carbon nanotubes for fluorescent/photoacoustic imaging-guided enhanced phototherapy. *Biomaterials* 2016, 103, 219–228. [CrossRef]

89. Attia, A.B.E.; Ho, C.J.H.; Chandrasekharan, P.; Balasundaram, G.; Tay, H.C.; Burton, N.C.; Chuang, K.-H.; Ntziachristos, V.; Olivo, M. Multispectral optoacoustic and MRI coregistration for molecular imaging of orthotopic model of human glioblastoma. *J. Biophoton.* 2016, 9, 701–708. [CrossRef] [PubMed]

90. Moon, H.; Kang, J.; Sim, C.; Kim, J.; Lee, H.; Chang, J.H.; Kim, H. Multifunctional theranostic contrast agent for photoacoustics- and ultrasound-based tumor diagnosis and ultrasound-stimulated local tumor therapy. *J. Control. Release* 2015, 218, 63–71. [CrossRef] [PubMed]

91. Sim, C.; Kim, H.; Moon, H.; Lee, H.; Chang, J.H.; Kim, H. Photoacoustic-based nanomedicine for cancer diagnosis and therapy. *J. Control. Release* 2015, 203, 118–125. [CrossRef] [PubMed]

92. Xie, C.; Upputuri, P.K.; Zhen, X.; Pramanik, M.; Pu, K. Self-Quenched Semiconducting Polymer Nanoparticles for Amplified In Vivo Photoacoustic Imaging. *Biomaterials* 2017, 119, 1–8. [CrossRef]

93. Zheng, X.; Ge, J.; Wu, J.; Liu, W.; Guo, L.; Jia, Q.; Ding, Y.; Zhang, H.; Wang, P. Biodegradable Hypocrellin Derivative Nanovesicle as a Near-Infrared Light-Derived Theranostic for Dually Phototive Cancer Imaging and Therapy. *Biomaterials* 2018, 185, 135–141. [CrossRef]

94. Lee, C.; Kwon, W.; Beack, S.; Lee, D.; Park, Y.; Kim, H.; Hahn, S.K.; Rhee, S.-W.; Kim, C. Biodegradable Nitrogen-Doped Carbon Nanodots for Non-Invasive Photoacoustic Imaging and Photothermal Therapy. *Theranostics* 2016, 6, 2196–2208. [CrossRef]

95. Li, X.; Zhang, D.; Yin, C.; Lu, G.; Wan, Y.; Huang, Z.; Tan, J.; Li, S.; Luo, J.; Lee, C.-S. A Diradicaloid Small Molecular Nanotheranostic with Strong Near-Infrared Absorbance for Effective Cancer Photoacoustic Imaging and Photothermal Therapy. *ACS Appl. Mater. Interfaces* 2021, 13, 15983–15991. [CrossRef]

96. Wang, J.-L.; Zhang, L.; Zhao, M.-J.; Zhang, T.; Liu, Y.; Jiang, F.-L. Mitochondria-Targeted BODIPY Nanoparticles for Enhanced Photothermal and Photothermal Imaging In Vivo. *ACS Appl. Bio Mater.* 2021, 4, 1760–1770. [CrossRef]

97. Li, D.; Zhang, Y.; Xu, J.; Yoshino, F.; Xu, H.; Chen, X.; Zhao, L. Surface-Engineered Carbon Nanohorns as a Theranostic Nanodevice for Photoacoustic Imaging and Effective Radiochemotherapy of Cancer. *Carbon* 2021, 180, 185–196. [CrossRef]

98. Liu, R.; Xu, F.; Wang, L.; Liu, M.; Cao, X.; Shi, X.; Guo, R. Polydopamine-Coated Lapumope Nanoplatforms for Photoacoustic Imaging-Guided Chemo-Therapeutic Agent for Breast Cancer. *Nanomater.* 2021, 11, 394. [CrossRef]

99. Cho, E.C.; Glaus, C.; Chen, J.; Welch, M.J.; Xia, Y. Inorganic Nanoparticle-Based Contrast Agents for Molecular Imaging. *Trends Mol. Med.* 2010, 16, 561–573. [CrossRef] [PubMed]

100. Li, J.; Arnal, B.; Wei, C.-W.; Shang, J.; Nguyen, T.-M.; O’Donnell, M.; Gao, X. Magneto-Optical Nanoparticles for Cyclic Magnetomotive Photoacoustic Imaging. *ACS Nano* 2015, 9, 1964–1976. [CrossRef] [PubMed]

101. O’Donnell, M. Magnetic Nanoparticles as Contrast Agents for Molecular Imaging in Medicine. *Phys. C Supercond. Appl.* 2018, 548, 103–106. [CrossRef]

102. Quyen Chau, N.D.; Ménard-Moyon, C.; Kostarelos, K.; Bianco, A. Multifunctional Carbon Nanomaterial Hybrids for Magnetic Manipulation and Targeting. *Biochem. Biophys. Res. Commun.* 2015, 468, 454–462. [CrossRef] [PubMed]

103. Yang, M.; Fan, Q.; Zhang, R.; Cheng, K.; Yan, J.; Pan, D.; Ma, X.; Lu, A.; Cheng, Z. Dragon Fruit-like Biocage as an Iron Trapping Nanoplatform for High Efficiency Targeted Cancer Multimodality Imaging. *Biomaterials* 2015, 69, 30–37. [CrossRef] [PubMed]

104. Wu, B.; Lu, S.-T.; Yu, H.; Liao, R.-F.; Li, H.; Lucie Zafitatsimo, B.V.; Li, Y.-S.; Zhang, Y.; Zhu, X.-L.; Liu, H.-G.; et al. Gadolinium-Chelate Functionalized Bismuth Nanotheranostic Agent for in Vivo MRI/CT/PAI Imaging-Guided Photothermal Cancer Therapy. *Biomaterials* 2018, 159, 37–47. [CrossRef] [PubMed]

105. Chang, X.; Zhang, Y.; Xu, P.; Zhang, M.; Wu, H.; Yang, S. Graphene Oxide/MnWO4 Nanocomposite for Magnetic Resonance/Photoacoustic Dual-Mode Imaging and Tumor Photothermo-Chemotherapy. *Carbon* 2018, 138, 397–409. [CrossRef]

106. Voti, R.L.; Leahu, G.; Sibilia, C.; Matassa, R.; Familiari, G.; Cerra, S.; Salamone, T.A.; Fratoddi, I. Photoacoustics for Listening to Metal Nanoparticle Super-Aggregates. *Nanoscale Adv.* 2021, 3, 4692–4701. [CrossRef]

107. Lamastra, F.R.; Grilli, M.L.; Leahu, G.; Belardini, A.; Li Voti, R.; Sibilia, C.; Salvatori, D.; Cacciotti, I.; Nanni, F. Diatom Frustules Decorated with Zinc Oxide Nanoparticles for Enhanced Optical Properties. *Nanotechnology* 2017, 28, 375704. [CrossRef]

108. Tan, L.; Wan, J.; Guo, W.; Ou, C.; Liu, T.; Fu, C.; Zhang, Q.; Ren, X.; Liang, X.-J.; Ren, J.; et al. Renal-Clearable Quaternary Chalcogenide Nanocrystal for Photoacoustic/Magnetic Resonance Imaging Guided Tumor Photothermal Therapy. *Biomaterials* 2018, 159, 108–118. [CrossRef] [PubMed]

109. Li, W.; Chen, X. Gold Nanoparticles for Photoacoustic Imaging. *Nanomedicine* 2015, 10, 299–320. [CrossRef] [PubMed]

110. Lee, S.; Lee, C.; Park, S.; Lim, K.; Kim, S.S.; Kim, J.O.; Lee, E.S.; Oh, K.T.; Choi, H.-G.; Youn, Y.S. Facile Fabrication of Highly Photothermal-Effective Albumin-Assisted Gold Nanoclusters for Treating Breast Cancer. *Int. J. Pharm.* 2018, 553, 363–374. [CrossRef] [PubMed]

111. Li, W.; Rong, P.; Yang, K.; Huang, P.; Sun, K.; Chen, X. Semimetal Nanomaterials of Antimony as Highly Efficient Agent for Photoacoustic Imaging and Tumor Photothermal Therapy. *Biomaterials* 2015, 45, 18–26. [CrossRef] [PubMed]

112. Hou, M.; Yan, C.; Chen, Z.; Zhao, Q.; Yuan, M.; Xu, Y.; Zhao, B. Multifunctional NIR-Responsive Poly(Vinylpyrrolidone)-Cu-Sb-S Nanotheranostic Agent for Photoacoustic Imaging and Photothermal/Photodynamic Therapy. *Acta Biomater.* 2018, 74, 334–343. [CrossRef] [PubMed]
113. Xu, L.; Hong, S.H.; Sun, Y.; Sun, Z.; Shou, K.; Cheng, K.; Chen, H.; Huang, D.; Xu, H.; Cheng, Z. Dual T1 and T2 Weighted Magnetic Resonance Imaging Based on Gd3+ Loaded Bioinspired Melanin Dots. *Nanomed. Nanotechnol. Biol. Med.* **2018**, *14*, 1743–1752. [CrossRef] [PubMed]

114. Hong, S.H.; Sun, Y.; Tang, C.; Cheng, K.; Zhang, R.; Fan, Q.; Xu, L.; Huang, D.; Zhao, A.; Cheng, Z. Chelator-Free and Biocompatible Melanin Nanoplatform with Facile-Loading Gadolinium and Copper-64 for Bioimaging. *Bioconj. Chem.* **2017**, *28*, 1925–1930. [CrossRef]

115. Liu, Q.; Qian, Y.; Li, P.; Zhang, S.; Wang, Z.; Liu, J.; Sun, X.; Fulham, M.; Feng, D.; Chen, Z.; et al. The Combined Therapeutic Effects of 131iodine-Labeled Multifunctional Copper Sulfide-Loaded Microspheres in Treating Breast Cancer. *Acta Pharm. Sin. B* **2018**, *8*, 371–380. [CrossRef]

116. Shen, S.; Ding, B.; Zhang, S.; Qi, X.; Wang, K.; Tian, J.; Yan, Y.; Ge, Y.; Wu, L. Near-Infrared Light-Responsive Nanoparticles with Thermosensitive Yolk-Shell Structure for Multimodal Imaging and Chemophotothermal Therapy of Tumor. *Nanomed. Nanotechnol. Biol. Med.* **2017**, *13*, 1607–1616. [CrossRef]

117. Feng, L.; Dong, Z.; Liang, C.; Chen, M.; Tao, D.; Cheng, L.; Yang, K.; Liu, Z. Iridium Nanocrystals Encapsulated Liposomes as Near-Infrared Light Controllable Nanoenzymes for Enhanced Cancer Radiotherapy. *Biomaterials* **2018**, *181*, 81–91. [CrossRef]

118. Tang, Y.; Yang, T.; Wang, Q.; Lv, X.; Song, X.; Ke, H.; Guo, Z.; Huang, X.; Hu, J.; Li, Z.; et al. Albumin-Coordinated Assembly of Clearable Platinum Nanodots for Photo-Induced Cancer Theranostics. *Biomaterials* **2018**, *154*, 248–260. [CrossRef]

119. Zhou, B.; Zhao, J.; Qiao, Y.; Wei, Q.; He, J.; Li, W.; Zhong, D.; Ma, F.; Li, Y.; Zhou, M. Simultaneous Multimodal Imaging and Photothermal Therapy via Renal-Clearable Manganese-Doped Copper Sulfide Nanodots. *Appl. Mater. Today* **2018**, *13*, 285–297. [CrossRef]

120. Tang, X.; Tan, L.; Shi, K.; Peng, J.; Xiao, Y.; Li, W.; Chen, L.; Yang, Q.; Qian, Z. Gold Nanorods Together with HSP Inhibitor-VER-155008 Micelles for Colon Cancer Mild-Temperature Photothermal Phototherapy. *Acta Pharm. Sin. B* **2018**, *8*, 587–601. [CrossRef] [PubMed]

121. Guo, Z.; Chen, M.; Peng, C.; Mo, S.; Shi, C.; Fu, G.; Wen, X.; Zhuang, R.; Su, X.; Liu, T.; et al. PH-Sensitive Radiolabeled and Superfluorininated Ultra-Small Palladium Nanosheet as a High-Performance Multimodal Platform for Tumor Theranostics. *Biomaterials* **2018**, *179*, 134–143. [CrossRef]

122. Liang, R.; Liu, L.; He, H.; Chen, Z.; Han, Z.; Luo, Z.; Wu, Z.; Zheng, M.; Ma, Y.; Cai, L. Oxygen-Boosted Immunogenic Photodynamic Therapy with Gold Nanocages@manganese Dioxide to Inhibit Tumor Growth and Metastases. *Biomaterials* **2018**, *177*, 149–160. [CrossRef] [PubMed]

123. He, W.; Ai, K.; Jiang, C.; Li, Y.; Song, X.; Lu, L. Plasmonic Titanium Nitride Nanoparticles for in Vivo Photoacoustic Tomography Imaging and Photothermal Cancer Therapy. *Biomaterials* **2017**, *132*, 37–47. [CrossRef]

124. Li, Z.; Liu, J.; Hu, Y.; Li, Z.; Fan, X.; Sun, Y.; Besenbacher, F.; Chen, C.; Yu, M. Biocompatible PEGylated Bismuth Nanocrystals: “All-in-one” Theranostic Agent with Triple-Modal Imaging and Efficient in Vivo Photothermal Ablation of Tumors. *Biomaterials* **2017**, *141*, 284–295. [CrossRef]

125. Yu, X.; Yang, K.; Chen, Z.; Li, W. Black Hollow Silicon Oxide Nanoparticles as Highly Efficient Photothermal Agents in the Second Near-Infrared Window for in Vivo Cancer Therapy. *Biomaterials* **2017**, *143*, 120–129. [CrossRef]

126. Zhou, G.; Xiao, H.; Li, X.; Huang, Y.; Song, W.; Song, L.; Chen, M.; Cheng, D.; Shuai, X. Gold Nanocage Decorated PH-Sensitive Micelle for Highly Effective Photothermal-Chemotherapy and Photoacoustic Imaging. *Acta Biomater.* **2017**, *64*, 223–236. [CrossRef]

127. Zhong, M.; Kim, H.S.; Jin, T.; Yi, A.; Moon, W.K. Ultrasound-Guided Photoacoustic Imaging for the Selective Detection of EGFR-Expressing Breast Cancer and Lymph Node Metastases. *Biomed. Opt. Express* **2016**, *7*, 1920–1931. [CrossRef]

128. Zhang, R.; Cheng, K.; Antaris, A.L.; Ma, X.; Yang, M.; Ramakrishnan, S.; Liu, G.; Lu, A.; Dai, H.; Tian, M.; et al. Hybrid Anisotropic Nanostructures for Dual-Modal Cancer Imaging and Image-Guided Chemo-Thermo Therapies. *Biomaterials* **2016**, *103*, 265–277. [CrossRef]

129. Zhong, J.; Yang, S.; Wen, L.; Xing, D. Imaging-Guided Photoacoustic Drug Release and Synergistic Chemo-Photothermal Therapy with Paclitaxel-Containing Nanoparticles. *J. Control. Release* **2016**, *226*, 77–87. [CrossRef] [PubMed]

130. Chou, S.-W.; Liu, C.-L.; Liu, T.-M.; Shen, Y.-F.; Kuo, L.-C.; Wu, C.-H.; Hsieh, T.-Y.; Wu, P.-C.; Tsai, M.-R.; Yang, C.-C.; et al. Infrared-Active Quadruple Contrast FePt Nanoparticles for Multiple Scale Molecular Imaging. *Biomaterials* **2016**, *85*, 54–64. [CrossRef] [PubMed]

131. Bao, T.; Yin, W.; Zheng, X.; Zhang, X.; Yu, J.; Dong, X.; Yong, Y.; Gao, F.; Yan, L.; Gu, Z.; et al. One-Pot Synthesis of PEGylated Plasmonic MoO3–x Hollow Nanospheres for Photoacoustic Imaging Guided Chemo-Photothermal Combinational Therapy of Cancer. *Biomaterials* **2016**, *76*, 11–24. [CrossRef] [PubMed]

132. Feng, Q.; Zhang, Y.; Zhang, W.; Shan, X.; Yuan, Y.; Zhang, H.; Hou, L.; Zhang, Z. Tumor-Targeted and Multi-Stimuli Responsive Drug Delivery System for near-Infrared Light Induced Chemo-Phototherapy and Photoacoustic Tomography. *Acta Biomater.* **2016**, *38*, 129–142. [CrossRef] [PubMed]

133. Anamaria, O.; Yang, Y.; Feng, T.; Wang, X.; Wu, H.; Li, Y.; Yang, L.; Tang, X.; Mao, H. A Nanocomposite of Au-AgI Core/Shell Dimer as a Dual-Modality Contrast Agent for x-Ray Computed Tomography and Photoacoustic Imaging. *Med. Phys.* **2016**, *43*, 589–599. [CrossRef]

134. Mallidi, S.; Kim, S.; Karpiouk, A.; Joshi, P.P.; Sokolov, K.; Emelianov, S. Visualization of Molecular Composition and Functionality of Cancer Cells Using Nanoparticle-Augmented Ultrasound-Guided Photoacoustics. *Photacoustics* **2015**, *3*, 26–34. [CrossRef] [PubMed]
135. Kanazaki, K.; Sano, K.; Makino, A.; Shimizu, Y.; Yamauchi, F.; Ogawa, S.; Ding, N.; Yano, T.; Temma, T.; Ono, M.; et al. Development of Anti-HER2 Fragment Antibody Conjugated to Iron Oxide Nanoparticles for in Vivo HER2-Targeted Photoacoustic Tumor Imaging. *Nanom. Nanotechnol. Biomed.* 2015, 11, 2051–2060. [CrossRef]

136. Mou, J.; Liu, C.; Li, P.; Chen, Y.; Xu, H.; Wei, C.; Song, L.; Shi, J.; Chen, H. A Facile Synthesis of Versatile Cu2-XS Nanoprobe for Enhanced MRI and Infrared/Photoacoustic Dual-Modality Imaging. *Biomater. 2015*, 57, 12–21. [CrossRef]

137. Kishimoto, S.; Oshima, N.; Yamamoto, K.; Munasinghe, J.; Ardenkjaer-Larsen, J.H.; Mitchell, J.B.; Cheyoke, P.L.; Krishna, M.C. Molecular Imaging of Tumor Photoimmunotherapy: Evidence of Photosensitized Tumor Necrosis and Hemodynamic Changes. *Free Radic. Biomed.* 2018, 116, 1–10. [CrossRef]

138. Samykutty, A.; Grizzle, W.E.; Fouts, B.L.; McNally, M.W.; Chuong, P.; Thomas, A.; Chiba, A.; Otali, D.; Woloszynska, A.; Said, N.; et al. Optoacoustic Imaging Identifies Ovarian Cancer Using a Microenvironment Targeted Theranostic Wormhole Mesoporous Silica Nanoparticle. *Biomater. 2018*, 182, 114–126. [CrossRef]

139. Haedicke, K.; Brand, C.; Omar, M.; Ntzisichristos, V.; Reiner, T.; Grimm, J. Sonophore Labeled RGD: A Targeted Contrast Agent for Optoacoustic Imaging. *Photacoustics 2017*, 6, 1–8. [CrossRef] [PubMed]

140. Lin, S.; Shah, A.; Hernández-Gil, J.; Stanzila, A.; Harriss, B.I.; Matsunaga, T.O.; Long, N.; Bamber, J.; Tang, M.-X. Optically and Acoustically Triggerable Sub-Micron Phase-Change Contrast Agents for Enhanced Photoacoustic and Ultrasound Imaging. *Photoacoustics 2017*, 6, 26–36. [CrossRef] [PubMed]

141. Li, Y.; Liu, G.; Ma, J.; Lin, J.; Lin, H.; Su, G.; Chen, D.; Ye, S.; Chen, X.; Zhu, X.; et al. Chemotherapeutic Drug-Photothermal Agent Co-Self-Assembling Nanoparticles for near-Infrared Fluorescence and Photoacoustic Dual-Modal Imaging-Guided Chemo-Photothermal Synergetic Therapy. *J. Control. Release 2017*, 258, 95–107. [CrossRef] [PubMed]

142. Wang, G.; Zhang, F.; Tian, R.; Zhang, L.; Fu, G.; Yang, L.; Zhu, L. Nanotubes-Embedded Indocyanine Green-Hyaluronic Acid Nanoparticles for Photoacoustic-Imaging-Guided Phototherapy. *ACS Appl. Mater. Interfaces 2016*, 8, 5608–5617. [CrossRef]

143. Chen, J.; Liu, C.; Zeng, G.; You, Y.; Wang, H.; Gong, X.; Zheng, R.; Kim, J.; Kim, C.; Song, L. Indocyanine Green Loaded Reduced Graphene Oxide for In Vivo Photoacoustic/Fluorescence Dual-Modality Tumor Imaging. *Nanoscale Res. Lett.* 2016, 11, 85. [CrossRef]

144. Yao, C.; Deng, Z.-J.; Peng, D.; Jin, Y.-S.; Ma, Y.; Li, Y.-Y.; Zhu, Y.-K.; Xi, J.-Z.; Tian, J.; Dai, Z.-F.; et al. Near-Infrared Dye-Loaded Magnetic Nanoparticles as Photoacoustic Contrast Agent for Enhanced Tumor Imaging. *Cancer Biol. Med.* 2016, 13, 349–359. [CrossRef]

145. Wang, J.; Guo, F.; Yu, M.; Liu, L.; Tan, F.; Yan, R.; Li, N. Rapamycin/DiR Loaded Lipid-Polyaniline Nanoparticles for Dual-Modal Imaging Guided Enhanced Photothermal and Antiangiogenic Combination Therapy. *J. Control. Release 2016*, 237, 23–34. [CrossRef]

146. Chen, Q.; Liu, X.; Zeng, J.; Cheng, Z.; Liu, Z. Albumin-NIR Dye Self-Assembled Nanoparticles for Photoacoustic PH Imaging and PH-Responsive Photothermal Therapy Effective for Large Tumors. *Biomater. 2016*, 98, 23–30. [CrossRef]

147. Zhang, Y.; Chen, W.; Yang, C.; Fan, Q.; Wu, W.; Jiang, X. Enhancing Tumor Penetration and Targeting Using Size-Minimized and Zwitterionic Nanomedicines. *J. Control. Release 2016*, 237, 115–124. [CrossRef]

148. Song, X.; Zhang, R.; Liang, C.; Chen, Q.; Gong, H.; Liu, Z. Nano-Assemblies of J-Aggregates Based on a NIR Dye as a Multifunctional Drug Carrier for Combination Cancer Therapy. *Biomater. 2015*, 57, 84–92. [CrossRef]

149. Beziere, N.; Lozano, N.; Nunes, A.; Salichs, J.; Queiros, D.; Kostarelos, K.; Ntzisichristos, V. Dynamic Imaging of PEGylated Indocyanine Green (ICG) Liposomes within the Tumor Microenvironment Using Multi-Spectral Optoacoustic Tomography (MSOT). *Biomater. 2015*, 37, 415–424. [CrossRef] [PubMed]

150. Yin, W.; Kimbrough, C.W.; Gomez-Gutierrez, J.G.; Burns, C.T.; Chuong, P.; Grizzle, W.E.; McNally, L.R. Tumor Specific Liposomes Improve Detection of Pancreatic Adenocarcinoma in Vivo Using Optoacoustic Tomography. *J. Nanobiotechnol.* 2015, 13, 90. [CrossRef] [PubMed]

151. Kimbrough, C.W.; Hudson, S.; Khanal, A.; Egger, M.E.; McNally, L.R. Orthotopic Pancreatic Tumors Detected by Optoacoustic Tomography Using Syndecan-1. *J. Surg. Res. 2015*, 193, 246–254. [CrossRef] [PubMed]

152. Yang, B.; Lin, H.; Dai, C.; Chen, Y.; Shi, J. “Stepwise Extraction” Strategy-Based Injectable Bioreposative Composite Implant for Cancer Theranostics. *Biomaterials 2018*, 166, 38–51. [CrossRef]

153. Zhang, W.; Deng, G.; Li, B.; Zhao, X.; Ji, T.; Song, G.; Xiao, Z.; Cao, Q.; Xiao, J.; Huang, X.; et al. Degradable Rhenium Trioxide Nanocubes with High Localized Surface Plasmon Resonance Absorbance like Gold for Photothermal Theranostics. *Biomaterials 2018*, 159, 68–81. [CrossRef]

154. Nagaoka, R.; Tabata, T.; Yoshizawa, S.; Umemura, S.; Saijo, Y. Visualization of Murine Lymph Vessels Using Photoacoustic Imaging with Contrast Agents. *Photoacoustics 2018*, 9, 39–48. [CrossRef]

155. Xu, C.; Chen, F.; Valdivinos, H.F.; Jiang, D.; Goel, S.; Yu, B.; Sun, H.; Barnhart, T.E.; Moon, J.J.; Cai, W. Bacteria-like Mesoporous Silica-Coated Gold Nanorods for Positron Emission Tomography and Photoacoustic Imaging-Guided Chemo-Photothermal Combined Therapy. *Biomater. 2018*, 165, 56–65. [CrossRef]

156. Luke, G.P.; Myers, J.N.; Emelianov, S.Y.; Sokolov, K. V Sentinel Lymph Node Biopsy Revisited: Ultrasound-Guided Photoacoustic Detection of Micrometastases Using Molecularly Targeted Plasmonic Nanosensors. *Cancer Res. 2014*, 74, 5397–5408. [CrossRef]

157. Cheng, X.; Zhou, X.; Xu, J.; Sun, R.; Xia, H.; Ding, J.; Chin, Y.E.; Chai, Z.; Shi, H.; Gao, M. Furin Enzyme and PH Synergistically Triggered Aggregation of Gold Nanoparticles for Activated Photoacoustic Imaging and Photothermal Therapy of Tumors. *Anal. Chem. 2021*, 93, 9277–9285. [CrossRef]

**Nanomaterials 2022, 12, 393**

23 of 24
158. Xi, L.; Grobmyer, S.R.; Zhou, G.; Qian, W.; Yang, L.; Jiang, H. Molecular Photoacoustic Tomography of Breast Cancer Using Receptor Targeted Magnetic Iron Oxide Nanoparticles as Contrast Agents. *J. Biophotonics* 2014, 7, 401–409. [CrossRef]
159. Zhou, M.; Ku, G.; Pageon, L.; Li, C. Theranostic Probe for Simultaneous in Vivo Photoacoustic Imaging and Confined Photothermalysis by Pulsed Laser at 1064 Nm in 4T1 Breast Cancer Model. *Nanoscale* 2014, 6, 15228–15235. [CrossRef] [PubMed]
160. Xiong, J.; Feng, J.; Qiu, L.; Gao, Z.; Li, P.; Pang, L.; Zhang, Z. SDF-1-Loaded PLGA Nanoparticles for the Targeted Photoacoustic Imaging and Photothermal Therapy of Metastatic Lymph Nodes in Tongue Squamous Cell Carcinoma. *Int. J. Pharm.* 2019, 554, 93–104. [CrossRef] [PubMed]
161. Yao, D.; Wang, Y.; Zou, R.; Bian, K.; Liu, P.; Shen, S.; Yang, W.; Zhang, B.; Wang, D. Molecular Engineered Squaraine Nanoprobe for NIR-II/Photoacoustic Imaging and Photothermal Therapy of Metastatic Breast Cancer. *ACS Appl. Mater. Interfaces* 2020, 12, 4276–4284. [CrossRef] [PubMed]
162. Zhao, J.; Jin, G.; Weng, G.; Li, J.; Zhu, J.; Zhao, J. Recent Advances in Activatable Fluorescence Imaging Probes for Tumor Imaging. *Drug Discov. Today* 2017, 22, 1367–1374. [CrossRef] [PubMed]
163. Bouvier-Müller, A.; Ducongé, F. Application of Aptamers for in Vivo Molecular Imaging and Theranostics. *Adv. Drug Deliv. Rev.* 2018, 134, 94–106. [CrossRef] [PubMed]
164. Yang, Y.; Xu, L.; Zhu, W.; Feng, L.; Liu, J.; Chen, Q.; Dong, Z.; Zhao, J.; Liu, Z.; Chen, M. One-Pot Synthesis of PH-Responsive Charge-Switchable PEGylated Nanoscale Coordination Polymers for Improved Cancer Therapy. *Biomaterials* 2018, 156, 121–133. [CrossRef] [PubMed]
165. Silva, M.L.S. Lectin-Based Biosensors as Analytical Tools for Clinical Oncology. *Cancer Lett.* 2018, 436, 63–74. [CrossRef]
166. Zhen, X.; Pu, K.; Jiang, X. Photoacoustic Imaging and Photothermal Therapy of Semiconducting Polymer Nanoparticles: Signal Amplification and Second Near-Infrared Construction. *Small* 2021, 17, 2004723. [CrossRef]
167. Goh, Y.; Balasundaram, G.; Moothanchery, M.; Attia, A.; Li, X.; Lim, H.Q.; Burton, N.; Qiu, Y.; Putti, T.C.; Chan, C.W.; et al. Multispectral Optoacoustic Tomography in Assessment of Breast Tumor Margins During Breast-Conserving Surgery: A First-in-Human Case Study. *Clin. Breast Cancer* 2018, 18, e1247–e1250. [CrossRef]
168. Vedantham, S.; Karellas, A. Emerging Breast Imaging Technologies on the Horizon. *Semin. Ultrasound, CT MRI* 2018, 39, 114–121. [CrossRef]